ABOUT THE RESEARCHER

OVERVIEW

Dr. Balan’s research studies are focused on identifying novel targets for cancer treatment including renal cancer. Dr. Balan’s research interest is to study the signal transduction pathways that modulate the growth, survival and killing of cancer cells; primarily focused on the receptor tyrosine kinases (RTKs)-mediated signaling pathways. In long term, Dr. Balan wish to comprehensively understand how Cytokines/RTKs-mediated signaling interferes with host anti-tumor immune responses and identify novel targets that can improve both targeted and immunotherapeutic approaches in the treatment of renal cancer.

BACKGROUND

After obtaining an engineering degree in Industrial Biotechnology (2003) from Anna University, Chennai, India, Dr. Balan completed his PhD in Biochemistry and Molecular biology (2010) from the University of Medicine and Dentistry of New Jersey (UMDNJ), Newark, USA (Mentor: Dr. Sergei Kotenko). In 2012, Dr. Balan joined Dr. Soumitro Pal’s laboratory at the Division of Nephrology, Boston Children’s Hospital for his post-doctoral research; and his research works on renal cancer cell signaling mechanisms have resulted in a number of important publications. In 2016, he was promoted as an Instructor, and, currently, as a Principal Investigator on NIH funded projects, his research studies are focused on identifying novel targets for the treatment of cancer including renal cancer.

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. A combination therapy using mTOR inhibitor and Honokiol effectively induces autophagy through the modulation of AXL and Rubicon in renal cancer cells, and restricts renal tumor growth following an organ transplantation. Carcinogenesis. 2021 Dec 29. View abstract
  2. Metabolic reprogramming in renal cancer: Events of a metabolic disease. Biochim Biophys Acta Rev Cancer. 2021 08; 1876(1):188559. View abstract
  3. Novel Honokiol-eluting PLGA-based scaffold effectively restricts the growth of renal cancer cells. PLoS One. 2020; 15(12):e0243837. View abstract
  4. Correction: A novel CXCR3-B chemokine receptor-induced growth-inhibitory signal in cancer cells is mediated through the regulation of Bach-1 protein and Nrf2 protein nuclear translocation. J Biol Chem. 2020 Jul 24; 295(30):10509. View abstract
  5. A Novel Combination Treatment with Honokiol and Rapamycin Effectively Restricts c-Met-Induced Growth of Renal Cancer Cells, and also Inhibits the Expression of Tumor Cell PD-L1 Involved in Immune Escape. Cancers (Basel). 2020 Jul 03; 12(7). View abstract
  6. Editorial: Tumor Microenvironment and Resistance to Current Therapies. Front Oncol. 2019; 9:1131. View abstract
  7. Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1. Oncogenesis. 2019 Jan 15; 8(2):7. View abstract
  8. Signaling Molecules in Posttransplantation Cancer. Clin Lab Med. 2019 03; 39(1):171-183. View abstract
  9. Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth. Sci Rep. 2017 07 19; 7(1):5900. View abstract
  10. Immunoevasion rather than intrinsic oncogenicity may confer MSCs from non-obese diabetic mice the ability to generate neural tumors. Acta Diabetol. 2017 Jul; 54(7):707-712. View abstract
  11. Correction: Distinct Roles of Type I and Type III Interferons in Intestinal Immunity to Homologous and Heterologous Rotavirus Infections. PLoS Pathog. 2016 06; 12(6):e1005726. View abstract
  12. Distinct Roles of Type I and Type III Interferons in Intestinal Immunity to Homologous and Heterologous Rotavirus Infections. PLoS Pathog. 2016 04; 12(4):e1005600. View abstract
  13. Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. J Biol Chem. 2015 Mar 27; 290(13):8110-20. View abstract
  14. High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting. Mol Cancer Res. 2015 Jan; 13(1):50-62. View abstract
  15. A novel CXCR3-B chemokine receptor-induced growth-inhibitory signal in cancer cells is mediated through the regulation of Bach-1 protein and Nrf2 protein nuclear translocation. J Biol Chem. 2014 Feb 07; 289(6):3126-37. View abstract
  16. Egr-1 is a critical regulator of EGF-receptor-mediated expansion of subventricular zone neural stem cells and progenitors during recovery from hypoxia-hypoglycemia. ASN Neuro. 2013 Jul 11; 5(3):183-93. View abstract
  17. Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol. 2011; 2011:349575. View abstract
  18. Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother. 2010 Jul; 59(7):1059-71. View abstract
  19. Brain injury expands the numbers of neural stem cells and progenitors in the SVZ by enhancing their responsiveness to EGF. ASN Neuro. 2009 May 20; 1(2). View abstract
  20. Murine models of chronic lymphocytic leukaemia: role of microRNA-16 in the New Zealand Black mouse model. Br J Haematol. 2007 Dec; 139(5):645-57. View abstract
  21. Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus. Proc Natl Acad Sci U S A. 2007 Jun 05; 104(23):9822-7. View abstract